Molecular Pharmacology Program
The Bayard Clarkson Lab
My laboratory focuses on the development of targeted therapies aimed at cancer stem cells.
Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones P, Djaballah H, Clarkson B, Larson SM. Synthesis and Biological evaluation of a Fluorine-18 derivative of Dasatinib.- Journal of Medicinal Chemistry, 50, (23), 5853-5857, 2007.
Wendel H G, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, and Lowe SW: Loss of p53 impedes the antileukemic response to BCR ABL inhibition. PNAS 103:7444 7449, 2006.
Azam M, Nardi V, Shakespeare WC, Metcalf III CA, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, and Daley GQ: Activity of dual SRC ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. PNAS 103:9244 9249, 2006.
Liang X, Hajivandi M, Veach D, Wisniewski D, Clarkson B, Resh, MD, and Pope MR: Quantification of change in phosphorylation of BCR ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics August; 6 (16): 4554-64, 2006.
Bayard Clarkson, MD
- Chemical biologist Bayard Clarkson focuses on the development of targeted therapies aimed at cancer stem cells.
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Bayard Clarkson discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.